口腔黏膜炎治療市場 - 按治療類型、藥物類別、配銷通路、最終用途和預測，2024 年至 2032 年

由於癌症發生率上升以及對有效治療的需求增加，口腔黏膜炎治療市場規模預計從 2024 年到 2032 年複合年成長率將達到 7.1%。醫療保健當局正在審查和批准新的治療方法，以解決接受化療和放射治療的癌症患者口腔黏膜炎的盛行率。

監管機構正在促進創新療法的批准，以減輕癌症患者的症狀並提高其生活品質。不斷加強研究力度，重點開發有針對性的、更有效的治療方法，以利用醫學科學技術的進步，將促進產業成長。例如，2023 年 2 月，美國 FDA 授予 Avasopasem 治療相關口腔黏膜炎的優先審查資格，承認其作為先進療法在解決化療對癌症患者口腔健康不利影響方面的潛力。

整個市場分為治療類型、藥物類別、配銷通路、最終用途和地區。

就治療類型而言，漱口水領域的口腔黏膜炎治療市場預計從 2024 年至 2032 年將錄得顯著的複合年成長率。由抗菌劑和舒緩劑等成分配製而成的漱口水有助於緩解正在接受癌症治療的患者的症狀。漱口水配方的進步導致新型化合物或靶向輸送系統的整合，以提高治療期間的功效和舒適度。

按配銷通路，在線藥房領域的口腔粘膜炎治療行業規模預計將在2024 年至2032 年期間上升。支持性護理產品的機會。這些平台還使患者能夠瀏覽各種治療方法，包括漱口水和其他專門用於緩解黏膜炎症狀的口腔護理產品。

從區域來看，在不斷提高口腔黏膜炎治療有效性和可及性的技術創新的推動下，亞太地區口腔黏膜炎治療市場規模預計將在 2024 年至 2032 年間呈現強勁成長。積極探索先進的漱口水配方和標靶輸送系統等創新，以改善症狀緩解和患者舒適度，促進區域產業的成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 癌症盛行率增加
    • 提高對支持性護理的認知和關注
    • 癌症治療方式的技術進步
  • 產業陷阱與挑戰
    • 治療費用高
    • 現有治療方法療效有限
• 成長潛力分析
• 監管環境
• 波特的分析
• PESTEL分析
• 未來市場趨勢

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按治療類型，2021 - 2032 年

• 主要趨勢
• 止痛藥
• 漱口水
• 其他治療類型

第 6 章：市場估計與預測：按藥物類別，2021 - 2032 年

• 主要趨勢
• 消炎劑
• 抗菌劑
• 抗真菌劑
• 抗腫瘤
• 抗生素
• 其他藥物類別

第 7 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

• 主要趨勢
• 醫院藥房
• 零售藥房
• 網路藥房

第 8 章：市場估計與預測：按最終用途，2021 - 2032 年

• 主要趨勢
• 醫院和診所
• 門診手術中心
• 其他最終用戶

第 9 章：市場估計與預測：按地區分類，2021 - 2032 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 10 章：公司簡介

• Amgen Inc.
• Basic Pharma Life Science Pvt Ltd.
• CANbridge Pharmaceuticals Inc.
• Enzychem Lifesciences Corporation
• EpicentRx, Inc.
• Galera Therapeutics, Inc.
• Helsinn Healthcare SA.
• Innovation Pharmaceuticals Inc.
• Monopar Therapeutics, Inc.
• Pfizer Inc.
• Soleva Pharma, LLC.
• Swedish Orphan Biovitrum AB

Oral Mucositis Treatment Market size is projected to record 7.1% CAGR from 2024 to 2032, driven by the rising rate of cancer along with the increased demand for effective therapies. Healthcare authorities are reviewing and approving new treatment methods to address the prevalence of oral mucositis among cancer patients undergoing chemotherapy and radiation therapy.

Regulatory agencies are facilitating the approval of innovative therapies for alleviating symptoms and improving the quality of life for cancer patients. Rising research efforts to focus on developing targeted and more efficacious treatment for leveraging advances in medical science and technology will boost the industry growth. For instance, in February 2023, the U.S. FDA granted Priority Review to Avasopasem for treatment-related oral mucositis for recognizing its potential as an advanced therapy in addressing the adverse effects of chemotherapy on oral health in cancer patients.

The overall market is segregated into treatment type, drug class, distribution channel, end-use, and region.

In terms of treatment type, the oral mucositis treatment market from the mouthwash segment is expected to record significant CAGR from 2024 to 2032. Mouthwash helps in soothing and managing symptoms, such as mouth pain and inflammation. Mouthwashes formulated with ingredients like antimicrobials and soothing agents are assisting in providing relief to patients undergoing cancer treatments. Advancements in mouthwash formulations are leading to the integration of novel compounds or targeted delivery systems to enhance efficacy and comfort during treatment.

By distribution channel, the oral mucositis treatment industry size from the online pharmacy segment is projected to rise from 2024 to 2032. Online pharmacies are offering convenience and accessibility for purchasing oral mucositis treatments for providing patients with easy access to medications and supportive care products. These platforms are also enabling patients to browse a variety of treatments including mouthwashes and other oral care products specifically designed to alleviate symptoms of mucositis.

Regionally, the Asia Pacific oral mucositis treatment market size is projected to exhibit robust growth between 2024 and 2032, fueled by the ongoing technological innovations for enhancing the effectiveness and accessibility of treatments for managing oral mucositis. Innovations, such as advanced mouthwash formulations and targeted delivery systems are actively explored to improve symptom relief and patient comfort, adding to the regional industry growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of cancer
    • 3.2.1.2 Growing awareness and focus on supportive care
    • 3.2.1.3 Technological advancements in cancer treatment modalities
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of treatments
    • 3.2.2.2 Limited efficacy of existing treatments
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis
• 3.7 Future market trends

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Pain control medication
• 5.3 Mouthwash
• 5.4 Other treatment types

Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Anti-inflammatory
• 6.3 Antimicrobials
• 6.4 Antifungal
• 6.5 Anti-neoplastic
• 6.6 Antibiotics
• 6.7 Other drug classes

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacy
• 7.3 Retail pharmacy
• 7.4 Online pharmacy

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals and clinics
• 8.3 Ambulatory surgical centers
• 8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Amgen Inc.
• 10.2 Basic Pharma Life Science Pvt Ltd.
• 10.3 CANbridge Pharmaceuticals Inc.
• 10.4 Enzychem Lifesciences Corporation
• 10.5 EpicentRx, Inc.
• 10.6 Galera Therapeutics, Inc.
• 10.7 Helsinn Healthcare SA.
• 10.8 Innovation Pharmaceuticals Inc.
• 10.9 Monopar Therapeutics, Inc.
• 10.10 Pfizer Inc.
• 10.11 Soleva Pharma, LLC.
• 10.12 Swedish Orphan Biovitrum AB